Novo Holdings silent on insider trading case
A representative for the Novo Nordisk owner has refused to say whether the company received insider trading information about Convatec from the company’s former chairman, who has been fined for his involvement.
by ulrich quistgaard, translated by daniel pedersen
Novo Holdings, the owner of Danish pharmaceutical firm Novo Nordisk, is tight-lipped when it comes to the insider trading case surrounding Sir Christopher Gent, former chairman of British medtech firm Convatec, reports Danish business media Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Convatec expects up to 5.5 percent growth in 2022
For subscribers
Chemometec CEO's wife convicted of insider trading
For subscribers
